Gerald D Wolf

US Patent:

20040047804, Mar 11, 2004

Filed:

Aug 12, 2003

Appl. No.:

10/639915

Inventors:

Gerald Wolf - Westboro MA, US
Gregory McIntire - West Chester PA, US
Edward Bacon - Audubon PA, US

Assignee:

The General Hospital Corporation, a Massachusetts corporation

International Classification:

A61K051/00

US Classification:

424/001110

Abstract:

The invention features new methods of enhanced radiation therapy based on the discovery that by using controlled combinations of (i) specific radiodense compositions, (ii) specific modes of administration of these radiodense compositions, and (iii) specific energy bands and sources of radiation, that the effect of radiation on tumors and other diseased tissues can be effectively and safely enhanced to provide significantly improved radiation therapy.

US Patent:

20050065184, Mar 24, 2005

Filed:

Aug 27, 2004

Appl. No.:

10/927790

Inventors:

Gerald Wolf - Westborough MA, US

International Classification:

A61K031/454
A61K031/401

US Classification:

514323000, 514423000

Abstract:

A method for ascertaining whether a subject has oxidative stress; evaluating the level of oxidative stress in a subject; reducing the risk of an adverse event, especially an adverse cardiovascular event, resulting from oxidative stress; treating oxidative stress; and evaluating the efficacy of treatment with at least one pharmaceutical composition for reducing oxidative stress is provided.

US Patent:

20090004113, Jan 1, 2009

Filed:

Jun 25, 2008

Appl. No.:

12/145565

Inventors:

Gerald L. Wolf - Westborough MA, US

Assignee:

AMAG PHARMACEUTICALS, INC. - Cambridge MA

International Classification:

A61K 49/06
A61K 49/00
A61B 5/055

US Classification:

424 92, 424 93, 600420

Abstract:

Methods for assessing stage of cancer in a subject are provided, comprising administering a macrophage imaging agent to the subject, making a magnetic resonance image of regions of the subject's body at cancer risk, and using the image to assess macrophage density and displacement associated with any primary cancer or metastatic cancer in the subject, such density and displacement being indicative of neoplasia. The macrophage imaging agent may be an ultrasmall superparamagnetic iron oxide particle and in particular embodiments, the macrophage imaging agent has a blood half-life sufficient to permit microphage trapping throughout the regions at cancer risk. Additional embodiments provide methods for assessing efficacy of an anticancer treatment in a subject, methods for determining frequency of follow-up MEMRI evaluation in a subject, methods for determining metastatic potential of cancer foci in a subject, and methods for determining prognosis of cancer in a subject. Methods for directing site of biopsy in a subject by performing a whole body MEMRI evaluation of the subject to identify macrophage density at a tumor site of interest and assessing the macrophage density to identify the site of biopsy in the subject, macrophage density being an indicator of tumor growth are also provided, in addition to methods for providing individualized cancer treatment to a subject in need thereof using whole body MEMRI evaluation.

US Patent:

20120003160, Jan 5, 2012

Filed:

Aug 3, 2011

Appl. No.:

13/197153

Inventors:

Gerald L. Wolf - Newton MA, US
Jerome M. Lewis - Newton MA, US

Assignee:

AMAG PHARMACEUTICALS, INC. - Lexington MA

International Classification:

A61K 49/08

US Classification:

424 932, 424 93, 424 936

Abstract:

Methods for performing macrophage-enhanced MRI, utilizing a macrophage imaging agent, in a single imaging session are provided. The macrophage imaging agent may be an ultrasmall superparamagnetic iron oxide particle. One embodiment includes administering a macrophage imaging agent to the subject during an administration session then allowing a passage of time sufficient for accumulation of the agent in macrophages of the subject. Subsequently, in a single imaging session, a macrophage-enhanced magnetic resonance image is acquired to target macrophages and a different magnetic resonance image is acquired to target physiological phenomenon other than macrophages. Additional embodiments provide methods wherein the acquisition of a different magnetic resonance image is achieved by vascular-enhanced MRI protocols or perfusion-enhanced MRI protocols, or combinations thereof. Further embodiments provide methods for utilizing acquired images in assessment of treatment of disease.

US Patent:

20130224073, Aug 29, 2013

Filed:

Nov 19, 2012

Appl. No.:

13/681343

Inventors:

Gerald Lee Wolf - Newton MA, US

International Classification:

G01N 27/72

US Classification:

422 69

Abstract:

A device that uses radiofrequency detection of the aggregation or disaggregation of magnetic nanoparticles without using nuclear magnetic resonance methods is described. The signals from one or more magnetic nanoparticle species in separate sample wells are compared to ascertain that aggregation or disaggregation has occurred. Depending on the specific reagents used, the detected aggregation or disaggregation event can be interpreted as an indicator of the presence of a molecule or microorganism of interest in a liquid sample.

US Patent:

20130336897, Dec 19, 2013

Filed:

Jun 18, 2013

Appl. No.:

13/920694

Inventors:

Gerald L. Wolf - Newton MA, US
Karl F. Schmidt - Watertown MA, US

International Classification:

A61K 49/18

US Classification:

424 936

Abstract:

Macrophages sequester and aggregate ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) in their lysosomes. The amount of USPIO loading of macrophages depends upon the route and dose of administration, and the pharmacokinetics of accumulation and removal. Both fixed macrophages and activated macrophages associated with inflammatory diseases and cancer phagocytize USPIOs, and the loaded macrophages can serve to identify the extent of a macrophage-dependent disease as well as to direct treatment options. Furthermore, the absorption of energy from incident electromagnetic waves by the aggregated nanoparticles can be used for conformal thermotherapy. The USPIOs can further be used to carry drugs to the same activated macrophages. The co-administered drugs can be bound to the USPIO by condition-dependent releasing links that are responsive to local pH or heating.

US Patent:

61637262, Dec 19, 2000

Filed:

Sep 21, 1998

Appl. No.:

9/158949

Inventors:

Gerald L. Wolf - Winchester MA

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61F 200

US Classification:

607101

Abstract:

The invention features a method for selectively ablating tumor-forming, glandular tissue in a breast by exposing the breast to microwave radiation that ablates glandular tissue while avoiding damage to the fatty tissues of the breast.

US Patent:

55674100, Oct 22, 1996

Filed:

Jun 24, 1994

Appl. No.:

8/265421

Inventors:

Vladimir P. Torchilin - Charlestown MA
Vladimir S. Trubetskoy - Milton MA
Gerald L. Wolf - Winchester MA
G. Scott Gazelle - Hingham MA

Assignee:

The General Hospital Corporation - Boston MA

International Classification:

A61K 4904
C07C 6310
C07C23365
C07C 2502

US Classification:

424 94

Abstract:

A radiographic imaging agent including a plurality of block copolymers forming a micelle, the block copolymers including a hydrophilic polymer linked to a hydrophobic polymer, and the hydrophobic polymer including a backbone incorporating radiopaque molecules via covalent bonds.